This is a revised competitive renewal application requesting continued support for the Anti-Cancer Drug Development training grant, T32 CA09243, presently in its 25th year. The training program is administered by the Department of Pharmacology & Molecular Sciences of the Johns Hopkins University School of Medicine, and its objective is to prepare pre- and postdoctoral students for research and teaching careers in the area of cancer-related drug development. ? ? Predoctoral training provides highly qualified students with an integrated curriculum including both course work and research. Rigorous core courses in the basic sciences are taken during the first year and include Molecular Biology, Biophysical Chemistry, Bio-organic Mechanisms, and Biochemistry and Cell Biology. Students receive additional instruction and exposure to pharmacology and oncology through the required Graduate Pharmacology course taken in the second year, and through elective courses, seminars, and journal clubs. Predoctoral trainees select a faculty preceptor and research project during their first two years, and devote most of their time after that to their thesis research and gaining experience with written and oral presentation of their work. Postdoctoral trainees devote most of their time to research carried out more independently, but with appropriate guidance from faculty mentors, for periods of one to three years. ? ? The training program is interdisciplinary and brings together faculty from 7 departments: Pharmacology & Molecular Sciences, Oncology, Biophysics & Biophysical Chemistry, Chemistry, Molecular Biology & Genetics, Urology, and Environmental Health Sciences. Extensive faculty interaction is promoted by common research interests, seminars and journal clubs, and by student-related activities such as recruiting weekends, research retreats, student-faculty dinners, and teaching. ? ? Since its beginning in 1979, this training program has supported over 100 pre- and postdoctoral trainees, most of whom have gone on to careers in science and many of whom have assumed leadership roles in the field of cancer research. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009243-27
Application #
6768844
Study Section
Subcommittee G - Education (NCI)
Program Officer
Eckstein, David J
Project Start
1978-09-30
Project End
2008-06-30
Budget Start
2004-09-24
Budget End
2005-06-30
Support Year
27
Fiscal Year
2004
Total Cost
$453,650
Indirect Cost
Name
Johns Hopkins University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Miles, Linde A; Burga, Laura N; Gardner, Eric E et al. (2017) Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus. J Clin Invest 127:2957-2967
Anglesio, Michael S; Papadopoulos, Nickolas; Ayhan, Ayse et al. (2017) Cancer-Associated Mutations in Endometriosis without Cancer. N Engl J Med 376:1835-1848
Perica, Karlo; Bieler, Joan Glick; Schütz, Christian et al. (2015) Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. ACS Nano 9:6861-71
Surcel, Alexandra; Ng, Win Pin; West-Foyle, Hoku et al. (2015) Pharmacological activation of myosin II paralogs to correct cell mechanics defects. Proc Natl Acad Sci U S A 112:1428-33
Ehrlich, Elana S; Chmura, Jennifer C; Smith, John C et al. (2014) KSHV RTA abolishes NF?B responsive gene expression during lytic reactivation by targeting vFLIP for degradation via the proteasome. PLoS One 9:e91359
Zinn, Rebekah L; Gardner, Eric E; Marchionni, Luigi et al. (2013) ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer. Mol Cancer Ther 12:1131-9
Zinn, Rebekah L; Gardner, Eric E; Dobromilskaya, Irina et al. (2013) Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer. Mol Cancer 12:16
Le, Dung T; Brockstedt, Dirk G; Nir-Paz, Ran et al. (2012) A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res 18:858-68
Titov, Denis V; Gilman, Benjamin; He, Qing-Li et al. (2011) XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol 7:182-8
Majumdar, Ananya; Sun, Yan; Shah, Meha et al. (2010) Versatile (1)H-(31)P-(31)P COSY 2D NMR techniques for the characterization of polyphosphorylated small molecules. J Org Chem 75:3214-23

Showing the most recent 10 out of 63 publications